ELANCO SHAREHOLDER NOTIFICATION: Elanco (NYSE:ELAN) Investors that Suffered an Investment Loss are Urged to Contact BFA Law about Ongoing Securities Fraud Investigation

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in ...